Compare VRTX & CMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | CMI |
|---|---|---|
| Founded | 1989 | 1919 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 98.9B |
| IPO Year | 2006 | 1994 |
| Metric | VRTX | CMI |
|---|---|---|
| Price | $491.20 | $686.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 14 |
| Target Price | $539.69 | ★ $587.69 |
| AVG Volume (30 Days) | ★ 1.3M | 918.2K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.25% |
| EPS Growth | ★ 836.54 | N/A |
| EPS | 4.02 | ★ 4.71 |
| Revenue | $2,488,652,000.00 | ★ $33,670,000,000.00 |
| Revenue This Year | $10.79 | $7.23 |
| Revenue Next Year | $10.47 | $8.58 |
| P/E Ratio | ★ $119.31 | $154.42 |
| Revenue Growth | ★ 46.20 | N/A |
| 52 Week Low | $362.50 | $322.45 |
| 52 Week High | $509.98 | $737.76 |
| Indicator | VRTX | CMI |
|---|---|---|
| Relative Strength Index (RSI) | 72.21 | 50.19 |
| Support Level | $420.66 | $631.63 |
| Resistance Level | $506.93 | $706.26 |
| Average True Range (ATR) | 12.22 | 23.97 |
| MACD | 4.26 | 1.59 |
| Stochastic Oscillator | 77.76 | 48.59 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Cummins is a leading manufacturer of diesel and other engines used in heavy- and medium-duty commercial trucks, off-highway equipment, and locomotives, in addition to prime power and standby generators. The company also sells powertrain components, which include filtration products, transmissions, turbochargers, aftertreatment systems, and fuel systems. Sales are approximately 60% US and Canada and 40% rest of the world. Much of Cummins' foreign sales (China, India, and so forth) are through joint ventures. The company operates 650 distributors and over 19,000 dealer locations across 190 countries. Cummins' business model is unique as it competes with many of its heavy-duty truck manufacturer customers, which also make their own engines.